‘Psyched’: MAPS Scores $30M, Mydecine Gets Psilocybin License, Psychedelic Science Sold

MAPS Gets $30M In Funds To Conclude MDMA Research

The Multidisciplinary Association for Psychedelic Studies recently completed a fundraising of $30 million. The funds will help MAPS finish the NGO’s ongoing research for MDMA-assisted psychotherapy in the treatment of post-traumatic stress disorder.

The campaign, labeled “The Capstone Challenge”, was launched in June of this year with the purpose of raising $10 million from independent donors.

Together with $10 million in hand and another $10 million that had been committed to the cause by other benefactors, MAPS managed to complete the necessary amount needed to finish the research and make the treatment of MDMA-assisted psychotherapy available for patients.

The campaign was successful thanks to donations from over 2,500 individual donors, that ranged from one dollar to $5 million.

MAPS will now move to execute the last part of its phase 3 clinical trials for MDMA, which will be conducted in the U.S., Canada and Israel.

Earlier this year the FDA allowed MAPS to finish the first part of the phase 3 trials early, due to very positive results.

“We could not have completed Capstone without PFSC and Tim Ferris,” said Rick Doblin, founder of MAPS, in a press conference on Thursday.

The PFSC, or Psychedelic Science Funders Collaborative, is another NGO which assisted …

Full story available on Benzinga.com

More 'Psyched': MAPS Scores $30M, Mydecine Gets Psilocybin License, Psychedelic Science Sold